Inventiva S.A. American Depository Shares (IVA) vs Verastem (VSTM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Verastem (VSTM) has outperformed Inventiva S.A. American Depository Shares (IVA) over the past year, losing 9.3% versus a loss of 38.1%. Over five years, IVA leads with a -75.2% price change compared with -75.5% for VSTM. Verastem is the larger company by market cap ($758.9 million vs $746.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IVA | VSTM |
|---|---|---|
| Share price | $3.16 | $8.38 |
| Market cap | $746.46M | $758.92M |
| 1-day change | -4.82% | +3.33% |
| YTD return | -28.60% | +5.05% |
| 1-year return | -38.06% | -9.28% |
| 5-year return | -75.22% | -75.51% |
| EPS (TTM) | $-0.62 | $-2.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.98 | $10.82 |
| 52-week low | $3.11 | $3.43 |
| Distance from 52-week high | -60.42% | -22.55% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +381.01% | +79.00% |
| Average volume | 1.39M | 2.25M |
| Shares outstanding | 236.22M | 90.56M |
| Employees | 87 | 102 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VSTM has outperformed IVA by 28.8 percentage points over the past year.
About Inventiva S.A. American Depository Shares
IVA stock →Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses.
Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees
About Verastem
VSTM stock →Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 102 employees
IVA vs VSTM FAQ
Which is bigger, Inventiva S.A. American Depository Shares or Verastem?
Verastem (VSTM) is larger, with a market capitalization of $758.92M compared with $746.46M for Inventiva S.A. American Depository Shares (IVA).
Which stock has performed better over the past year, IVA or VSTM?
VSTM returned -9.28% over the past 12 months, compared with -38.06% for IVA (price return, excluding dividends). Past performance does not predict future results.
Are Inventiva S.A. American Depository Shares and Verastem in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.